

# Current Clinical Controversies and Promising Therapeutic Strategies in Non-Small Cell Lung Cancer

*A Live Clinical Investigator Think Tank Symposium at ASCO 2010*

## TARGET AUDIENCE

This activity is intended for medical oncologists, radiation oncologists, thoracic surgeons and other allied healthcare professionals involved in the treatment of non-small cell lung cancer (NSCLC).

## LEARNING OBJECTIVES

- Apply the results of emerging clinical research to the current and future treatment of NSCLC.
- Counsel patients with localized NSCLC about the risk-adjusted, long-term clinical impact of adjuvant chemotherapy.
- Use biomarkers, clinical characteristics and tumor histology to select individualized front-line treatment approaches for patients with NSCLC.
- Identify patients with metastatic NSCLC who may experience clinical benefit from the addition of maintenance biologic therapy and/or chemotherapy.
- Educate appropriately selected patients about the benefits and risks of combination chemotherapy and bevacizumab or cetuximab.
- Recognize the effect of NSCLC tumor-specific mutations on relative response or resistance to treatment with EGFR TKIs and monoclonal antibodies.
- Recall ongoing research strategies in the multimodality management of Stage III NSCLC.

## ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

## CREDIT DESIGNATION STATEMENT

Research To Practice designates this audio activity for a maximum of 0.75 *AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

## HOW TO USE THIS CME ACTIVITY

This CME activity consists of an audio component. To receive credit, the participant should listen to the audio content and complete the Educational Assessment and Credit Form located on our website at [ResearchToPractice.com/ISSLung11/CME](http://ResearchToPractice.com/ISSLung11/CME).

## CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

**FACULTY** — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

### Thomas J Lynch Jr, MD

Director, Yale Cancer Center  
Physician-in-Chief, Smilow Cancer  
Hospital at Yale New Haven  
New Haven, Connecticut

**Board of Directors:** Infinity Pharmaceuticals Inc; **Consulting Agreements:** AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Merck and Company Inc; **Stock Ownership:** Biogen Idec.

### Chandra P Belani, MD

Miriam Beckner Distinguished Professor of Medicine  
Penn State College of Medicine  
Deputy Director  
Penn State Cancer Institute  
Hershey, Pennsylvania

**Consulting Agreements:** Amgen Inc, Genentech BioOncology, Lilly USA LLC, Pfizer Inc.

### Vincent A Miller, MD

Associate Attending Physician  
Thoracic Oncology Service  
Memorial Sloan-Kettering Cancer Center  
New York, New York

**Consultancy or Advisory Role and Honoraria:** Cylene Pharmaceuticals, Genentech BioOncology, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis.

**Mark A Socinski, MD**

Professor of Medicine  
Multidisciplinary Thoracic Oncology Program  
Lineberger Comprehensive Cancer Center  
University of North Carolina  
Chapel Hill, North Carolina

**Data and Safety Monitoring Board:** Bayer HealthCare Pharmaceuticals; **Paid Research:** Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Lilly USA LLC, Pfizer Inc; **Speakers Bureau:** Genentech BioOncology, GlaxoSmithKline, Lilly USA LLC, Sanofi-Aventis.

**Jean-Charles Soria, MD, PhD**

Full Professor, Paris University XI  
Division of Cancer Medicine  
Institut Gustave Roussy  
Villejuif, France

**Consulting Agreements:** AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Lilly USA LLC, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis, Wyeth.

**MODERATOR** — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/ Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Millennium — The Takeda Oncology Company, Myriad

Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Seattle Genetics.

**RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS**

— The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

This program is supported by an educational grant from Lilly USA LLC.

**Hardware/Software Requirements:**

An Internet connection that is at least 28.8 Kbps  
A monitor set to 1280 x 1024 pixels or more  
Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer  
Macromedia Flash plug-in 6.0 or greater  
Adobe Acrobat Reader  
(Optional) Sound card and speakers for audio

**Last review date:** April 2011

**Expiration date:** April 2012

This presentation was selected by the American Society of Clinical Oncology® as an independent educational activity held adjunct to the ASCO Annual Meeting. This presentation is not sponsored or endorsed by ASCO.